{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:00:29Z","timestamp":1779915629831,"version":"3.53.1"},"reference-count":40,"publisher":"Federa\u00e7\u00e3o das Associa\u00e7\u00f5es de Ginecologia e Obstetr\u00edcia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,25]]},"DOI":"10.61622\/rbgo\/2024fps05","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T16:14:46Z","timestamp":1714666486000},"source":"Crossref","is-referenced-by-count":4,"title":["Hyperprolactinemia in women: treatment"],"prefix":"10.61622","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-5593","authenticated-orcid":false,"given":"Cristina Laguna","family":"Benetti-Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-0206","authenticated-orcid":false,"given":"Andrea Prestes","family":"N\u00e1cul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-344X","authenticated-orcid":false,"given":"Ana Carolina Japur","family":"Rosa e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9097-8528","authenticated-orcid":false,"given":"Gustavo Arantes Rosa","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-4167","authenticated-orcid":false,"given":"Vania","family":"dos Santos Nunes Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-4813","authenticated-orcid":false,"given":"Paula Cond\u00e9 Lamparelli","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-9552","authenticated-orcid":false,"given":"Manoel","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-3192","authenticated-orcid":false,"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-8548","authenticated-orcid":false,"given":"Heraldo Mendes","family":"Garmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8201-6756","authenticated-orcid":false,"given":"Andrea","family":"Glezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"47794","reference":[{"issue":"2","key":"key20240502121415_B1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. doi: 10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20240502121415_B2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.20945\/2359-3997000000032","article-title":"Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism","volume":"62","author":"Vilar","year":"2018","unstructured":"Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, et al. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(2):236-63. doi: 10.20945\/2359-3997000000032","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"key20240502121415_B3","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/bcp.15660","article-title":"Dopamine agonists for the treatment of pituitary tumours: from ergot extracts to next generation therapies","volume":"89","author":"Wexler","year":"2023","unstructured":"Wexler TL, Page-Wilson G. Dopamine agonists for the treatment of pituitary tumours: from ergot extracts to next generation therapies. Br J Clin Pharmacol. 2023;89(4):1304-17. doi: 10.1111\/bcp.15660","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"key20240502121415_B4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","unstructured":"Dekkers OM, Lagro J, Burman P, J\u00f8rgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(1):43-51. doi: 10.1210\/jc.2009-1238","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20240502121415_B5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","unstructured":"Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50-61. doi: 10.1007\/s12020-017-1444-9","journal-title":"Endocrine"},{"issue":"5","key":"key20240502121415_B6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11102-013-0525-x","article-title":"Second attempt to withdraw cabergoline in prolactinomas: a pilot study","volume":"17","author":"Kwancharoen","year":"2014","unstructured":"Kwancharoen R, Auriemma RS, Yenokyan G, Wand GS, Colao A, Salvatori R. Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary. 2014;17(5):451-6. doi: 10.1007\/s11102-013-0525-x","journal-title":"Pituitary"},{"key":"key20240502121415_B7","doi-asserted-by":"crossref","first-page":"105124","DOI":"10.1016\/j.phrs.2020.105124","article-title":"Dopamine receptors in emesis: molecular mechanisms and potential therapeutic function","volume":"161","author":"Belkacemi","year":"2020","unstructured":"Belkacemi L, Darmani NA. Dopamine receptors in emesis: molecular mechanisms and potential therapeutic function. Pharmacol Res. 2020;161:105124. doi: 10.1016\/j.phrs.2020.105124","journal-title":"Pharmacol Res"},{"issue":"10","key":"key20240502121415_B8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/ncpendmet0290","article-title":"Management of resistant prolactinomas","volume":"2","author":"Olafsdottir","year":"2006","unstructured":"Olafsdottir A, Schlechte J. Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab. 2006;2(10):552-61. doi: 10.1038\/ncpendmet0290","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"3","key":"key20240502121415_B9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"dos Santos Nunes","year":"2011","unstructured":"dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011;14(3):259-65. doi: 10.1007\/s11102-010-0290-z","journal-title":"Pituitary"},{"issue":"14","key":"key20240502121415_B10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331(14):904-9. doi: 10.1056\/NEJM199410063311403","journal-title":"N Engl J Med"},{"issue":"6","key":"key20240502121415_B11","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2165\/00003495-199651060-00004","article-title":"Diagnosis and drug therapy of prolactinoma","volume":"51","author":"Ciccarelli","year":"1996","unstructured":"Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs. 1996;51(6):954-65. doi: 10.2165\/00003495-199651060-00004","journal-title":"Drugs"},{"issue":"1","key":"key20240502121415_B12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356(1):39-46. doi: 10.1056\/NEJMoa054830","journal-title":"N Engl J Med"},{"issue":"2","key":"key20240502121415_B13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2018-01071","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline","volume":"104","author":"Stiles","year":"2019","unstructured":"Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. J Clin Endocrinol Metab. 2019;104(2):523-38. doi: 10.1210\/jc.2018-01071.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20240502121415_B14","doi-asserted-by":"crossref","first-page":"e2452","DOI":"10.1210\/clinem\/dgab073","article-title":"A hard look at cardiac safety with dopamine agonists in endocrinology","volume":"106","author":"Daly","year":"2021","unstructured":"Daly AF, Beckers A. A hard look at cardiac safety with dopamine agonists in endocrinology. J Clin Endocrinol Metab. 2021;106(6):e2452-4. doi: 10.1210\/clinem\/dgab073","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20240502121415_B15","first-page":"1089","article-title":"Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy","volume":"23","author":"Hamidianjahromi","year":"2022","unstructured":"Hamidianjahromi A, Tritos NA. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord. 2022;23(5):1089-99. doi: 10.1007\/s11154-022-09753-6","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"key20240502121415_B16","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1210\/clinem\/dgac718","article-title":"A genetic assessment of dopamine agonist-induced impulse control disorder in patients with prolactinoma","volume":"108","author":"Sahin","year":"2023","unstructured":"Sahin S, Sudutan T, Kavla Y, Durcan E, \u00d6zogul YY, Poyraz BC, et al. A genetic assessment of dopamine agonist-induced impulse control disorder in patients with prolactinoma. J Clin Endocrinol Metab. 2023;108(6):e275-82. doi: 10.1210\/clinem\/dgac718","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20240502121415_B17","doi-asserted-by":"crossref","DOI":"10.3171\/2012.4.FOCUS1268","article-title":"Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature","volume":"32","author":"Lam","year":"2012","unstructured":"Lam G, Mehta V, Zada G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. Neurosurg Focus. 2012;32(6):E2. doi: 10.3171\/2012.4.FOCUS1268","journal-title":"Neurosurg Focus"},{"issue":"3","key":"key20240502121415_B18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1590\/2359-3997000000047","article-title":"Pituitary apoplexy: pathophysiology, diagnosis and management","volume":"59","author":"Glezer","year":"2015","unstructured":"Glezer A, Bronstein MD. Pituitary apoplexy: pathophysiology, diagnosis and management. Arch Endocrinol Metab. 2015;59(3):259-64. doi: 10.1590\/2359-3997000000047","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"key20240502121415_B19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","unstructured":"Maiter D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2019;109(1):42-50. doi: 10.1159\/000495775","journal-title":"Neuroendocrinology"},{"issue":"3","key":"key20240502121415_B20","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.4158\/EP10369.CR","article-title":"Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas","volume":"17","author":"Iyer","year":"2011","unstructured":"Iyer P, Molitch ME. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Endocr Pract. 2011;17(3):e55-8. doi: 10.4158\/EP10369.CR","journal-title":"Endocr Pract"},{"issue":"3","key":"key20240502121415_B21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","article-title":"Pituitary tumors centers of excellence","volume":"49","author":"Frara","year":"2020","unstructured":"Frara S, Rodriguez-Carnero G, Formenti AM, Martinez-Olmos MA, Giustina A, Casanueva FF. Pituitary tumors centers of excellence. Endocrinol Metab Clin North Am. 2020;49(3):553-64. doi: 10.1016\/j.ecl.2020.05.010","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"key20240502121415_B22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ecl.2014.11.003","article-title":"Prolactinomas","volume":"44","author":"Glezer","year":"2015","unstructured":"Glezer A, Bronstein MD. Prolactinomas. Endocrinol Metab Clin North Am. 2015;44(1):71-8. doi: 10.1016\/j.ecl.2014.11.003","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"key20240502121415_B23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","article-title":"A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas","volume":"23","author":"Sant'Anna","year":"2020","unstructured":"Sant'Anna BG, Musolino NR, Gadelha MR, Marques C, Castro M, Elias PC, et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary. 2020;23(2):120-8. doi: 10.1007\/s11102-019-01008-z","journal-title":"Pituitary"},{"issue":"1","key":"key20240502121415_B24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11102-019-01010-5","article-title":"Prolactinomas in pregnancy: considerations before conception and during pregnancy","volume":"23","author":"Glezer","year":"2020","unstructured":"Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary. 2020;23(1):65-9. doi: 10.1007\/s11102-019-01010-5","journal-title":"Pituitary"},{"issue":"9","key":"key20240502121415_B25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BM, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(9):722-40. doi: 10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"key20240502121415_B26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ando.2016.04.001","article-title":"Prolactinoma and pregnancy: from the wish of conception to lactation","volume":"77","author":"Maiter","year":"2016","unstructured":"Maiter D. Prolactinoma and pregnancy: from the wish of conception to lactation. Ann Endocrinol (Paris). 2016;77(2):128-34. doi: 10.1016\/j.ando.2016.04.001","journal-title":"Ann Endocrinol (Paris)"},{"issue":"5","key":"key20240502121415_B27","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/EJE-14-0848","article-title":"Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma","volume":"172","author":"Molitch","year":"2015","unstructured":"Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205-13. doi: 10.1530\/EJE-14-0848","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"key20240502121415_B28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4103\/ijem.ijem_372_21","article-title":"Prolactinoma outcome after pregnancy and lactation: a cohort study","volume":"25","author":"Laway","year":"2021","unstructured":"Laway BA, Baba MS, Bansiwal SK, Choh NA. Prolactinoma outcome after pregnancy and lactation: a cohort study. Indian J Endocrinol Metab. 2021;25(6):559-62. doi: 10.4103\/ijem.ijem_372_21","journal-title":"Indian J Endocrinol Metab"},{"issue":"2","key":"key20240502121415_B29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00404-014-3210-z","article-title":"Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database","volume":"290","author":"Hurault-Delarue","year":"2014","unstructured":"Hurault-Delarue C, Montastruc JL, Beau AB, Lacroix I, Damase-Michel C. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet. 2014;290(2):263-70. doi: 10.1007\/s00404-014-3210-z","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"key20240502121415_B30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-9378(72)90446-2","article-title":"Studies of prolactin secretion in human pregnancy","volume":"113","author":"Tyson","year":"1972","unstructured":"Tyson JE, Hwang P, Guyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol. 1972;113(1):14-20. doi: 10.1016\/0002-9378(72)90446-2","journal-title":"Am J Obstet Gynecol"},{"key":"key20240502121415_B31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/IJWH.S232693","article-title":"Is cabergoline safe and effective for postpartum lactation inhibition? A systematic review","volume":"12","author":"Yang","year":"2020","unstructured":"Yang Y, Boucoiran I, Tulloch KJ, Poliquin V. Is cabergoline safe and effective for postpartum lactation inhibition? A systematic review. Int J Womens Health. 2020;12:159-70. doi: 10.2147\/IJWH.S232693","journal-title":"Int J Womens Health"},{"issue":"1","key":"key20240502121415_B32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11102-019-00998-0","article-title":"Prolactinomas and menopause: any changes in management?","volume":"23","author":"Greenman","year":"2020","unstructured":"Greenman Y. Prolactinomas and menopause: any changes in management? Pituitary. 2020;23(1):58-64. doi: 10.1007\/s11102-019-00998-0","journal-title":"Pituitary"},{"issue":"7","key":"key20240502121415_B33","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/09513590.2015.1017810","article-title":"Hyperprolactinemia: pathophysiology and therapeutic approach","volume":"31","author":"Capozzi","year":"2015","unstructured":"Capozzi A, Scambia G, Pontecorvi A, Lello S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol. 2015;31(7):506-10. doi: 10.3109\/09513590.2015.1017810","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"key20240502121415_B34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cen.13399","article-title":"Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes","volume":"87","author":"Santharam","year":"2017","unstructured":"Santharam S, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes. Clin Endocrinol (Oxf). 2017;87(5):508-14. doi: 10.1111\/cen.13399","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key20240502121415_B35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.maturitas.2021.06.014","article-title":"Hyperprolactinemia after menopause: diagnosis and management","volume":"151","author":"Auriemma","year":"2021","unstructured":"Auriemma RS, Pirchio R, Pivonello R, Colao A. Hyperprolactinemia after menopause: diagnosis and management. Maturitas. 2021;151:36-40. doi: 10.1016\/j.maturitas.2021.06.014","journal-title":"Maturitas"},{"issue":"3","key":"key20240502121415_B36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinaemia","volume":"54","author":"Karunakaran","year":"2001","unstructured":"Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001;54(3):295-300. doi: 10.1046\/j.1365-2265.2001.01190.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"key20240502121415_B37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1590\/2359-3997000000138","article-title":"Prolactinomas: evolution after menopause","volume":"60","author":"Mallea-Gil","year":"2016","unstructured":"Mallea-Gil MS, Manavela M, Alfieri A, Ballarino MC, Chervin A, Danilowicz K, Prolactinomas: evolution after menopause. Arch Endocrinol Metab. 2016;60(1):42-6. doi: 10.1590\/2359-3997000000138","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"key20240502121415_B38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cen.13765","article-title":"Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal","volume":"89","author":"Santharam","year":"2018","unstructured":"Santharam S, Fountas A, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf). 2018;89(3):346-53. doi: 10.1111\/cen.13765","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"key20240502121415_B39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12020-014-0259-1","article-title":"Women with prolactinomas presented at the postmenopausal period","volume":"47","author":"Shimon","year":"2014","unstructured":"Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A. Women with prolactinomas presented at the postmenopausal period. Endocrine. 2014;47(3):889-94. doi: 10.1007\/s12020-014-0259-1","journal-title":"Endocrine"},{"issue":"1","key":"key20240502121415_B40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","article-title":"Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis","volume":"12","author":"Lu","year":"2022","unstructured":"Lu Z, Sun Y, Zhang Y, Chen Y, Guo L, Liao Y, Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis. Transl Psychiatry. 2022;12(1):267. doi: 10.1038\/s41398-022-02027-4","journal-title":"Transl Psychiatry"}],"container-title":["Revista Brasileira de Ginecologia e Obstetr\u00edcia \/ RBGO Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journalrbgo.org\/wp-content\/uploads\/sites\/4\/articles_xml\/1806-9339-rbgo-46-e-fps05\/1806-9339-rbgo-46-e-fps05.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:52:26Z","timestamp":1724345546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalrbgo.org\/article\/hyperprolactinemia-in-women-treatment\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":40,"alternative-id":["10.61622\/rbgo\/2024FPS05"],"URL":"https:\/\/doi.org\/10.61622\/rbgo\/2024fps05","relation":{},"ISSN":["0100-7203","1806-9339"],"issn-type":[{"value":"0100-7203","type":"print"},{"value":"1806-9339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e-FPS05"}}